| Jenny Potgieter, FNP | |
|
1031 7th St Ne, Devils Lake, ND 58301-2719 | |
| (701) 662-2131 | |
| Not Available |
| Full Name | Jenny Potgieter |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Location | 1031 7th St Ne, Devils Lake, North Dakota |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1336887827 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363L00000X | Nurse Practitioner | R32412 (North Dakota) | Primary |
| Entity Name | Carrington Health Center |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1205807013 PECOS PAC ID: 0547177552 Enrollment ID: O20020822000021 |
News Archive
Afatinib has a novel mode of action and data has shown that it offers a clinical benefit to patients with a specific type of lung cancer, which we are further investigating in the extensive LUX-Lung clinical trial programme.
A new study from the Smidt Heart Institute at Cedars-Sinai and other centers nationwide shows that patients who underwent a minimally invasive transcatheter aortic-valve replacement, had similar key 5-year clinical outcomes of death and stroke as patients who had traditional open-heart surgery to replace the valve.
Myriad Pharmaceuticals, Inc. today announced the presentation of clinical data from two separate Phase 2a combination drug studies of AzixaTM (MPC-6827, verubulin) at the American Society of Clinical Oncology 2010 Annual Meeting in Chicago, IL. Results from studies in both recurrent glioblastoma multiforme and stage 4 metastatic melanoma demonstrated that Azixa, in combination with standard treatments, resulted in durable responses with no added toxicity compared with chemotherapy alone.
The Washington Post reports on Duke University's experiment with community health centers Duke University has been focusing closer attention on the neighborhood that surrounds it by forming a partnership with Durham's Federally Qualified Health Center.
Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Levetiracetam Tablets, 250 mg, 500 mg and 750 mg. Levetiracetam Tablets are the generic version of UCB Pharma's Keppra.
› Verified 1 days ago
| Entity Name | Carrington Health Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1558389338 PECOS PAC ID: 0547177552 Enrollment ID: O20040810000314 |
News Archive
Afatinib has a novel mode of action and data has shown that it offers a clinical benefit to patients with a specific type of lung cancer, which we are further investigating in the extensive LUX-Lung clinical trial programme.
A new study from the Smidt Heart Institute at Cedars-Sinai and other centers nationwide shows that patients who underwent a minimally invasive transcatheter aortic-valve replacement, had similar key 5-year clinical outcomes of death and stroke as patients who had traditional open-heart surgery to replace the valve.
Myriad Pharmaceuticals, Inc. today announced the presentation of clinical data from two separate Phase 2a combination drug studies of AzixaTM (MPC-6827, verubulin) at the American Society of Clinical Oncology 2010 Annual Meeting in Chicago, IL. Results from studies in both recurrent glioblastoma multiforme and stage 4 metastatic melanoma demonstrated that Azixa, in combination with standard treatments, resulted in durable responses with no added toxicity compared with chemotherapy alone.
The Washington Post reports on Duke University's experiment with community health centers Duke University has been focusing closer attention on the neighborhood that surrounds it by forming a partnership with Durham's Federally Qualified Health Center.
Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Levetiracetam Tablets, 250 mg, 500 mg and 750 mg. Levetiracetam Tablets are the generic version of UCB Pharma's Keppra.
› Verified 1 days ago
| Entity Name | Mercy Hospital Of Devils Lake |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1790751170 PECOS PAC ID: 9537128681 Enrollment ID: O20041005001141 |
News Archive
Afatinib has a novel mode of action and data has shown that it offers a clinical benefit to patients with a specific type of lung cancer, which we are further investigating in the extensive LUX-Lung clinical trial programme.
A new study from the Smidt Heart Institute at Cedars-Sinai and other centers nationwide shows that patients who underwent a minimally invasive transcatheter aortic-valve replacement, had similar key 5-year clinical outcomes of death and stroke as patients who had traditional open-heart surgery to replace the valve.
Myriad Pharmaceuticals, Inc. today announced the presentation of clinical data from two separate Phase 2a combination drug studies of AzixaTM (MPC-6827, verubulin) at the American Society of Clinical Oncology 2010 Annual Meeting in Chicago, IL. Results from studies in both recurrent glioblastoma multiforme and stage 4 metastatic melanoma demonstrated that Azixa, in combination with standard treatments, resulted in durable responses with no added toxicity compared with chemotherapy alone.
The Washington Post reports on Duke University's experiment with community health centers Duke University has been focusing closer attention on the neighborhood that surrounds it by forming a partnership with Durham's Federally Qualified Health Center.
Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Levetiracetam Tablets, 250 mg, 500 mg and 750 mg. Levetiracetam Tablets are the generic version of UCB Pharma's Keppra.
› Verified 1 days ago
| Entity Name | Mercy Hospital Of Devils Lake |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1659343093 PECOS PAC ID: 9537128681 Enrollment ID: O20070521000292 |
News Archive
Afatinib has a novel mode of action and data has shown that it offers a clinical benefit to patients with a specific type of lung cancer, which we are further investigating in the extensive LUX-Lung clinical trial programme.
A new study from the Smidt Heart Institute at Cedars-Sinai and other centers nationwide shows that patients who underwent a minimally invasive transcatheter aortic-valve replacement, had similar key 5-year clinical outcomes of death and stroke as patients who had traditional open-heart surgery to replace the valve.
Myriad Pharmaceuticals, Inc. today announced the presentation of clinical data from two separate Phase 2a combination drug studies of AzixaTM (MPC-6827, verubulin) at the American Society of Clinical Oncology 2010 Annual Meeting in Chicago, IL. Results from studies in both recurrent glioblastoma multiforme and stage 4 metastatic melanoma demonstrated that Azixa, in combination with standard treatments, resulted in durable responses with no added toxicity compared with chemotherapy alone.
The Washington Post reports on Duke University's experiment with community health centers Duke University has been focusing closer attention on the neighborhood that surrounds it by forming a partnership with Durham's Federally Qualified Health Center.
Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Levetiracetam Tablets, 250 mg, 500 mg and 750 mg. Levetiracetam Tablets are the generic version of UCB Pharma's Keppra.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jenny Potgieter, FNP 1031 7th St Ne, Devils Lake, ND 58301-2719 Ph: (701) 662-2131 | Jenny Potgieter, FNP 1031 7th St Ne, Devils Lake, ND 58301-2719 Ph: (701) 662-2131 |
News Archive
Afatinib has a novel mode of action and data has shown that it offers a clinical benefit to patients with a specific type of lung cancer, which we are further investigating in the extensive LUX-Lung clinical trial programme.
A new study from the Smidt Heart Institute at Cedars-Sinai and other centers nationwide shows that patients who underwent a minimally invasive transcatheter aortic-valve replacement, had similar key 5-year clinical outcomes of death and stroke as patients who had traditional open-heart surgery to replace the valve.
Myriad Pharmaceuticals, Inc. today announced the presentation of clinical data from two separate Phase 2a combination drug studies of AzixaTM (MPC-6827, verubulin) at the American Society of Clinical Oncology 2010 Annual Meeting in Chicago, IL. Results from studies in both recurrent glioblastoma multiforme and stage 4 metastatic melanoma demonstrated that Azixa, in combination with standard treatments, resulted in durable responses with no added toxicity compared with chemotherapy alone.
The Washington Post reports on Duke University's experiment with community health centers Duke University has been focusing closer attention on the neighborhood that surrounds it by forming a partnership with Durham's Federally Qualified Health Center.
Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Levetiracetam Tablets, 250 mg, 500 mg and 750 mg. Levetiracetam Tablets are the generic version of UCB Pharma's Keppra.
› Verified 1 days ago
Kelsey Vivatson, PMHNP-BC, APRN Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 210 Highway 2 W Ste 10, Devils Lake, ND 58301 Phone: 701-662-1046 | |
Stella Onyeakazi, FNP-BC Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1001 7th St. Ne- Altru Clinic Devils Lake, Devils Lake, ND 58301 Phone: 701-662-2157 | |
Luann J Stromme, DNP,FNP-C Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 200 Highway 2 W, Devils Lake, ND 58301 Phone: 701-665-2200 Fax: 701-665-2300 | |
Megan Overby, FNP-C Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1001 7th St Ne, Devils Lake, ND 58301 Phone: 701-662-2157 | |
Carlee Lynn Thomson, DNP, APRN, FNP-C Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1031 7th St Ne, Devils Lake, ND 58301 Phone: 701-662-2131 | |
Billie J Madler, FNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 1001 7th St Ne, Devils Lake, ND 58301 Phone: 701-662-2157 |